Filing Details
- Accession Number:
- 0001593968-23-000441
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-09 17:12:40
- Reporting Period:
- 2023-03-09
- Accepted Time:
- 2023-03-09 17:12:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1771917 | Karuna Therapeutics Inc. | KRTX | Pharmaceutical Preparations (2834) | 270605902 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1777631 | K. Stephen Brannan | C/O Karuna Therapeutics, Inc. 99 High Street, 26Th Floor Boston MA 02110 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-03-09 | 5,000 | $5.45 | 28,650 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-03-09 | 5,000 | $189.51 | 23,650 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Option (right to buy) | Disposition | 2023-03-09 | 5,000 | $0.00 | 5,000 | $5.45 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 24,677 | 2027-06-01 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2022.
- This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
Billionaire Hedge Funds
